Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug. In an interview with Endpoints News
When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at “most favored nation” prices, my mind immediately turned to
Metsera has now received new takeover bids from both Pfizer and Novo Nordisk, and has plumped for a sweetened $10bn offer from the latter.
Plus, news about Kaigene, Celltrion, Solid Bio, Terns Pharmaceuticals, Benitec, Pacira, AmacaThera, UCB, Basilea Pharmaceutica, Pfizer, Kura Oncology, Kyowa Kirin, Novavax, Sanofi, Syndexis and Relmada:
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in
AstraZeneca and Organon have breached the UK pharma industry’s code of practice with promotions for an asthma drug and a contraceptive implant.
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844